165 related articles for article (PubMed ID: 30100995)
41. Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer.
Yun EJ; Zhou J; Lin CJ; Hernandez E; Fazli L; Gleave M; Hsieh JT
Clin Cancer Res; 2016 Feb; 22(3):670-9. PubMed ID: 26490309
[TBL] [Abstract][Full Text] [Related]
42. Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways.
Hansen SN; Westergaard D; Thomsen MB; Vistesen M; Do KN; Fogh L; Belling KC; Wang J; Yang H; Gupta R; Ditzel HJ; Moreira J; Brünner N; Stenvang J; Schrohl AS
Tumour Biol; 2015 Jun; 36(6):4327-38. PubMed ID: 25596703
[TBL] [Abstract][Full Text] [Related]
43. Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells.
Ma Y; Miao Y; Peng Z; Sandgren J; De Ståhl TD; Huss M; Lennartsson L; Liu Y; Nistér M; Nilsson S; Li C
Springerplus; 2016; 5(1):1861. PubMed ID: 27822437
[TBL] [Abstract][Full Text] [Related]
44. B4GALT1 Is a New Candidate to Maintain the Stemness of Lung Cancer Stem Cells.
De Vitis C; Corleone G; Salvati V; Ascenzi F; Pallocca M; De Nicola F; Fanciulli M; di Martino S; Bruschini S; Napoli C; Ricci A; Bassi M; Venuta F; Rendina EA; Ciliberto G; Mancini R
J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31717588
[TBL] [Abstract][Full Text] [Related]
45. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
46. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc.
Izumi D; Ishimoto T; Miyake K; Eto T; Arima K; Kiyozumi Y; Uchihara T; Kurashige J; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Watanabe M; Goel A; Tan P; Baba H
Stem Cells; 2017 Sep; 35(9):2027-2036. PubMed ID: 28699179
[TBL] [Abstract][Full Text] [Related]
47. Identifying global expression patterns and key regulators in epithelial to mesenchymal transition through multi-study integration.
Parsana P; Amend SR; Hernandez J; Pienta KJ; Battle A
BMC Cancer; 2017 Jun; 17(1):447. PubMed ID: 28651527
[TBL] [Abstract][Full Text] [Related]
48. Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.
Hotte SJ
Future Oncol; 2017 Feb; 13(4):369-379. PubMed ID: 27712093
[TBL] [Abstract][Full Text] [Related]
49. The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Gravina GL; Marampon F; Petini F; Biordi L; Sherris D; Jannini EA; Tombolini V; Festuccia C
Endocr Relat Cancer; 2011 Aug; 18(4):385-400. PubMed ID: 21551258
[TBL] [Abstract][Full Text] [Related]
50. Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer.
Chen L; Xu YX; Wang YS; Ren YY; Chen YM; Zheng C; Xie T; Jia YJ; Zhou JL
J Ethnopharmacol; 2024 Sep; 331():118265. PubMed ID: 38677579
[TBL] [Abstract][Full Text] [Related]
51. Genetic Signatures for Distinguishing Chemo-Sensitive from Chemo-Resistant Responders in Prostate Cancer Patients.
Gumenku L; Sekhoacha M; Abrahams B; Mashele S; Shoko A; Erukainure OL
Curr Issues Mol Biol; 2024 Mar; 46(3):2263-2277. PubMed ID: 38534761
[TBL] [Abstract][Full Text] [Related]
52. A proteomic investigation of isogenic radiation resistant prostate cancer cell lines.
Kurganovs N; Wang H; Huang X; Ignatchenko V; Macklin A; Khan S; Downes MR; Boutros PC; Liu SK; Kislinger T
Proteomics Clin Appl; 2021 Sep; 15(5):e2100037. PubMed ID: 34152685
[TBL] [Abstract][Full Text] [Related]
53. Digital Therapies (DTx) as New Tools within Physicians' Therapeutic Arsenal: Key Observations to Support their Effective and Responsible Development and Use.
Bélisle-Pipon JC; David PM
Pharmaceut Med; 2023 Mar; 37(2):121-127. PubMed ID: 36653600
[TBL] [Abstract][Full Text] [Related]
54. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
Cevatemre B; Bulut I; Dedeoglu B; Isiklar A; Syed H; Bayram OY; Bagci-Onder T; Acilan C
Cell Death Dis; 2024 Feb; 15(2):132. PubMed ID: 38346967
[TBL] [Abstract][Full Text] [Related]
55. Comprehensive transcriptomic profiling of liver cancer identifies that histone and PTEN are major regulators of SCU‑induced antitumor activity.
Ha SE; Paramanantham A; Kim HH; Bhosale PB; Park MY; Abusaliya A; Heo JD; Lee WS; Kim GS
Oncol Lett; 2024 Mar; 27(3):94. PubMed ID: 38288037
[TBL] [Abstract][Full Text] [Related]
56. Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer Cells.
Sanchez-Hernandez ES; Ochoa PT; Suzuki T; Ortiz-Hernandez GL; Unternaehrer JJ; Alkashgari HR; Diaz Osterman CJ; Martinez SR; Chen Z; Kremsky I; Wang C; Casiano CA
Cells; 2023 Aug; 12(16):. PubMed ID: 37626856
[TBL] [Abstract][Full Text] [Related]
57. Glucocorticoid Receptor and β-Catenin Interact in Prostate Cancer Cells and Their Co-Inhibition Attenuates Tumorsphere Formation, Stemness, and Docetaxel Resistance.
Martinez SR; Elix CC; Ochoa PT; Sanchez-Hernandez ES; Alkashgari HR; Ortiz-Hernandez GL; Zhang L; Casiano CA
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108293
[TBL] [Abstract][Full Text] [Related]
58. PTEN Protein Phosphatase Activity Is Not Required for Tumour Suppression in the Mouse Prostate.
Wise HM; Harris A; Kriplani N; Schofield A; Caldwell H; Arends MJ; Overton IM; Leslie NR
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291720
[TBL] [Abstract][Full Text] [Related]
59. The LEDGF/p75 Integrase Binding Domain Interactome Contributes to the Survival, Clonogenicity, and Tumorsphere Formation of Docetaxel-Resistant Prostate Cancer Cells.
Ortiz-Hernandez GL; Sanchez-Hernandez ES; Ochoa PT; Elix CC; Alkashgari HR; McMullen JRW; Soto U; Martinez SR; Diaz Osterman CJ; Mahler M; Roy S; Casiano CA
Cells; 2021 Oct; 10(10):. PubMed ID: 34685704
[TBL] [Abstract][Full Text] [Related]
60. Transcriptome analysis of sinensetin-treated liver cancer cells guided by biological network analysis.
Kim SM; Rampogu S; Vetrivel P; Kulkarni AM; Ha SE; Kim HH; Lee KW; Kim GS
Oncol Lett; 2021 May; 21(5):355. PubMed ID: 33747212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
